Zhang HM, Wang GH, Sun SW, Yuan L. Advancing prognostic precision in gastric cancer with an immunoinflammatory index. World J Gastroenterol 2024; 30(44): 4754-4758 [DOI: 10.3748/wjg.v30.i44.4754]
Corresponding Author of This Article
Lei Yuan, PhD, Professor, Department of Hepatobiliary Surgery, Quzhou People’s Hospital, No. 100 Minjiang Main Road, Quzhou 324000, Zhejiang Province, China. icbbsuse@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 28, 2024; 30(44): 4754-4758 Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4754
Advancing prognostic precision in gastric cancer with an immunoinflammatory index
Hong-Mei Zhang, Guo-Hua Wang, Shan-Wen Sun, Lei Yuan
Hong-Mei Zhang, Shan-Wen Sun, College of Life Science, Northeast Forestry University, Harbin 150040, Heilongjiang Province, China
Guo-Hua Wang, College of Computer and Control Engineering, Northeast Forestry University, Harbin 150040, Heilongjiang Province, China
Lei Yuan, Department of Hepatobiliary Surgery, Quzhou People’s Hospital, Quzhou 324000, Zhejiang Province, China
Co-corresponding authors: Shan-Wen Sun and Lei Yuan.
Author contributions: Yuan L and Sun SW contributed equally to this work and should be considered co-corresponding authors. Zhang HM and Yuan L conceived this study and implemented the experiments; Wang GH and Sun SW reviewed the literature; Zhang HM drafted the manuscript; Sun SW and Yuan L revised the manuscript.
Supported bythe National Natural Science Foundation of China, No. 62273086; and the Fundamental Research Funds for the Central Universities, No. 2572022BD04.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lei Yuan, PhD, Professor, Department of Hepatobiliary Surgery, Quzhou People’s Hospital, No. 100 Minjiang Main Road, Quzhou 324000, Zhejiang Province, China. icbbsuse@sina.com
Received: July 29, 2024 Revised: October 12, 2024 Accepted: October 23, 2024 Published online: November 28, 2024 Processing time: 105 Days and 20.9 Hours
Abstract
Gastric cancer remains a major global health challenge with high morbidity and mortality rates. Recent advancements in immunology and inflammation research have highlighted the crucial roles that these biological processes play in tumor progression and patient outcomes. This has sparked new interest in developing prognostic biomarkers that integrate these two key biological processes. In this letter, we discuss the recent study by Ba et al, which proposed a novel prognostic immunoinflammatory index for patients with gastric cancer. We underscore the importance of this research, its potential impact on medical practice, and the prospective avenues for further investigation in this rapidly emerging area of study.
Core Tip: This letter discusses the study by Ba et al on the development of a novel prognostic index for gastric cancer by integrating immune-inflammatory biomarkers and lymphocyte subsets. This index is closely associated with tumour characteristics and can serve as an independent prognostic factor for both progression-free survival and overall survival. This innovative approach holds promise for improving patient stratification, personalizing treatment, and ultimately enhancing patient outcomes.
